Pharmacyclics reports results of Ibrutinib Phase II study for Waldenstrom's Macroglobulinemia

Clinical-stage biopharmaceutical company Pharmacyclics has announced results from Phase II study of oral Bruton's tyrosine kinase (BTK) inhibitor, Ibrutinib, conducted in patients with Waldenstrom's Macroglobulinemia (WM).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news